COST-EFFECTIVENESS OF HIV PrEP AMONG YOUNG MEN WHO HAVE SEX WITH MEN IN THE US
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) studies 110/113 found oral tenofovir disoproxil fumarate/emtricitabine (F/TDF) HIV pre-exposure prophylaxis (PrEP) to be safe and feasible among young men who have sex with men (YMSM, ages 13-24). However, questions remain about the cost-effectiveness of PrEP in this population with low adherence and retention. We used a…